Key Insights

Highlights

Success Rate

80% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

12.0%

3 terminated out of 25 trials

Success Rate

80.0%

-6.5% vs benchmark

Late-Stage Pipeline

24%

6 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results80% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (5)
Early P 1 (1)
P 1 (1)
P 2 (4)
P 3 (3)
P 4 (3)

Trial Status

Completed12
Recruiting5
Terminated3
Active Not Recruiting1
Withdrawn1
Suspended1

Trial Success Rate

80.0%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (25)

Showing 20 of 20 trials
NCT03926520Not ApplicableRecruiting

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

NCT05543681Phase 2Recruiting

Clinical Trial on Agitation in Alzheimer's Dementia

NCT04075435Early Phase 1Active Not Recruiting

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

NCT06041646Phase 4Completed

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT03513549SuspendedPrimary

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

NCT05658510Phase 3CompletedPrimary

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05783505Not ApplicableRecruitingPrimary

A Multicomponent Intervention Program to Prevent and Reduce ICU Agitation and Physical Restraint Use

NCT02504450CompletedPrimary

Outcomes of Antipsychotic Medication Used in the Emergency Department

NCT06620393Phase 2Not Yet Recruiting

Effects of Dexmedetomidine on Agitation in Critically Ill TBI Patients

NCT05612711Phase 2Withdrawn

Dronabinol for Agitation in Dementia Crossover Trial

NCT06217146Not ApplicableTerminatedPrimary

A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.

NCT05765162Recruiting

Safe Brain Initiative, Operationalizing Precision Anaesthesia

NCT04053426CompletedPrimary

Agitation Follow up After Introduction of a New Patient Care Algorithm

NCT04957238Not ApplicableRecruiting

Physical Restraints in Intensive Care Unit Patients

NCT04797715Phase 3Completed

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

NCT04251910Phase 1CompletedPrimary

Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia

NCT03226522Phase 2Completed

Addressing Dementia Via Agitation-Centered Evaluation

NCT04276883Phase 3Completed

Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder

NCT03208452Phase 4CompletedPrimary

The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation

NCT05272501Not ApplicableCompleted

CAlming Touch for People With Agitation or Other Behavioural Symptoms of DEMentia - A Randomized Feasibility Trial

Scroll to load more

Research Network

Activity Timeline